The National Lipid Association (NLA) has released updated guidance for clinicians on identifying patients for which proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor therapy would provide reasonable value. Currently, two PCSK9 therapies have been approved by the Food and Drug Administration. Alirocumab is indicated as an adjunct to diet, alone or in combination with…
Investigators substantiated strategies to encourage approval rates for proprotein convertase subtilisin/kexin type 9 inhibitors.
Investigators used Mendelian randomization analysis to determine the amount of lipoprotein(a) reduction needed to match the effect on coronary heart disease outcomes that lowering low-density lipoprotein cholesterol has.
Oral infections in childhood are associated with subclinical carotid atherosclerosis in adulthood.
Metabolic syndrome has traditionally been described as having 3 or more cardiovascular risk factors such as altered glucose metabolism, hypertension, abdominal obesity, and dyslipidemia.
Patients with stable ischemic heart disease and diabetes have improved survival when risk factors such as lifestyle behaviors and glycated hemoglobin A1c level are controlled.
Researchers identified 2 lipid ratios that were useful markers for metabolic syndrome in adolescents with central adiposity.
The FDA has approved Praluent (alirocumab; Sanofi and Regeneron), a PCSK9 inhibitor, to reduce the risk of myocardial infarction (MI), stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
Polyvascular disease is associated with high risks of major adverse cardiovascular events and death despite intensive statin therapy.
Suboptimal responders have increased risk for incident cardiovascular disease
